Abstract

BackgroundChronic infection with hepatitis B (HBV) is a known risk factor for increased mortality from hepatocellular carcinoma (HCC) and chronic liver disease (CLD). However, the specific effects of chronic HBV infection on life expectancy have not been adequately studied. Taiwan is endemic for HBV infection, and thus provides sufficient information for such estimates.MethodsPopulation mortality statistics, combined with data on the contribution of HBV to HCC and CLD deaths, were used to model carrier mortality by sex and e antigen status. An abridged life table was used to calculate carrier life expectancy.ResultsAmong both males and females, those who are e antigen-positive are more likely to die from HCC than from CLD. When e antigen status remains positive, absolute liver mortality rates climb significantly after age 40 years. CLD is a proportionally higher threat for e antigen-negative females than for other subgroups. Males have higher liver-related mortality at all ages. A small decrease in life expectancy, from 82.0 to 80.1 years, was found for female noncarriers versus female carriers; a larger discrepancy was observed for males—from 76.2 to 71.8 years. In comparison to noncarriers, the lifetime relative risk of mortality is 1.35 for male carriers and 1.16 for female carriers.ConclusionsThese results indicate that chronic HBV infection results in significant liver-related mortality; however, carriers retain a satisfactory life expectancy.

Highlights

  • There are an estimated 350 million chronic carriers of hepatitis B virus (HBV) in the world.[1]

  • Because it has been reported that there were no significant differences in non-liver-related mortality between HBV carriers and noncarriers,[7] non-liverrelated deaths were calculated by subtracting mortality associated with liver cancer and chronic liver disease from overall mortality rates

  • Hepatitis B e antigen (HbeAg) prevalence is the percentage of Hepatitis B surface antigen (HbsAg) carriers who are HbeAg-positive

Read more

Summary

Introduction

There are an estimated 350 million chronic carriers of hepatitis B virus (HBV) in the world.[1]. Life expectancy and mortality data would aid clinicians in offering prognoses, which would benefit the many patients who report feelings of depression related to insufficient prognostic information.[12] Public health epidemiologists can use this model to estimate regional disease burden and predict the results of vaccination and treatment interventions. This method of estimating carrier life expectancy can be applied to determine the cost-effectiveness of treatment and may potentially influence drug reimbursement schedules. Conclusions: These results indicate that chronic HBV infection results in significant liver-related mortality; carriers retain a satisfactory life expectancy

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call